Edition:
United States

Voyager Therapeutics Inc (VYGR.OQ)

VYGR.OQ on NASDAQ Stock Exchange Global Select Market

19.90USD
17 Jul 2018
Change (% chg)

-- (--)
Prev Close
$19.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
175,331
52-wk High
$31.91
52-wk Low
$8.10

Chart for

About

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company's pipeline consists of programs for CNS indications, including advanced Parkinson's disease; a monogenic form of amyotrophi... (more)

Overall

Beta: --
Market Cap(Mil.): $557.18
Shares Outstanding(Mil.): 26.90
Dividend: --
Yield (%): --

Financials

  VYGR.OQ Industry Sector
P/E (TTM): -- 85.36 32.76
EPS (TTM): -2.30 -- --
ROI: -35.17 2.21 14.61
ROE: -45.36 3.85 16.34

BRIEF-Voyager Therapeutics Rpeorts Q1 GAAP Loss Per Share Of $0.63

* VOYAGER THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS

May 10 2018

BRIEF-Voyager Therapeutics Reports Q4 GAAP Loss Per Share $0.40

* VOYAGER THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 14 2018

BRIEF-Voyager Therapeutics Announces Longer-Term Data From Ongoing Phase 1B Trial Of VY-AADC For Advanced Parkinson’s Disease

* VOYAGER THERAPEUTICS ANNOUNCES LONGER-TERM DATA FROM ONGOING PHASE 1B TRIAL OF VY-AADC FOR ADVANCED PARKINSON’S DISEASE

Mar 09 2018

BRIEF-Voyager Therapeutics And Abbvie Announce Global Strategic Collaboration

* VOYAGER THERAPEUTICS AND ABBVIE ANNOUNCE GLOBAL STRATEGIC COLLABORATION TO DEVELOP POTENTIAL NEW TREATMENTS FOR ALZHEIMER’S DISEASE AND OTHER TAU-RELATED NEURODEGENERATIVE DISEASES

Feb 20 2018

BRIEF-Voyager Therapeutics Announces FDA Clearance Of Investigational NDA For VY-AADC

* VOYAGER THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR VY-AADC FOR ADVANCED PARKINSON’S DISEASE

Jan 23 2018

Earnings vs. Estimates